Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Phagocytosis of Apoptotic Cells in Resolution of Inflammation

Ioannis Kourtzelis, George Hajishengallis, Triantafyllos Chavakis

Frontiers in Immunology · 2020 · Review · CC BY

doi:10.3389/fimmu.2020.00553

Abstract

Efficient inflammation resolution is important not only for the termination of the inflammatory response but also for the restoration of tissue integrity. An integral process to resolution of inflammation is the phagocytosis of dying cells by macrophages, known as efferocytosis. This function is mediated by a complex and well-orchestrated network of interactions amongst specialized phagocytic receptors, bridging molecules, as well as "find-me" and "eat-me" signals. Efferocytosis serves not only as a waste disposal mechanism (clearance of the apoptotic cells) but also promotes a pro-resolving phenotype in efferocytic macrophages and thereby termination of inflammation. Alterations in cellular metabolism are critical for shaping the phenotype and function of efferocytic macrophages, thus, representing an important determinant of macrophage plasticity. Impaired efferocytosis can result in inflammation-associated pathologies or autoimmunity. The present mini review summarizes current knowledge regarding the mechanisms regulating macrophage efferocytosis during clearance of inflammation.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Specific recognition and engulfment of “foreign” material or pathogens by host cells, designated as phagocytosis, is an essential process modulating the immune response and tissue homeostasis. Besides phagocytosis of opsonized pathogens by phagocytes during an infection, host cells undergoing apoptosis are also cleared by macrophages; the specific phagocytosis of dying cells by macrophages is designated efferocytosis. The specific pathways for phagocytosis of different types of cargo point to the versatility of the phagocytic machinery.

A central player in sterile inflammation or inflammation associated with infection are neutrophils recruited to the inflamed site. Recruited neutrophils phagocytose and kill pathogens, produce reactive oxygen species (ROS) and pro-inflammatory factors, such as cytokines, and can either release neutrophil extracellular traps (NETs) or undergo apoptosis. Efferocytosis is therefore of great importance in the regulation of neutrophilic inflammation. Effective removal of dying neutrophils promotes not only inflammation resolution but also contributes to restoration of tissue and organ homeostasis. A complex network of interactions between receptors mediating phagocytosis, bridging molecules, “find-me” and “eat-me” signals, such as phosphatidylserine (PS), which is presented on the outer part of the membrane of cells undergoing apoptosis, contributes to the formation of phagocytic synapse (Figure 1) and the operation of the efferocytic machinery. As resolution of inflammation occurs, efferocytic macrophages acquire a resolving phenotype producing factors that dampen inflammation and promote restoration of tissue integrity, such as IL-10 or transforming growth factor β (TGFβ), as as well as specialized pro-resolving lipid mediators (SPM), such as resolvins, lipoxins, and maresins. SPM synthesis can further promote efferocytosis, thereby further potentiating inflammation resolution. Defective removal of apoptotic cells resulting from impaired efferocytosis can lead to chronicity of inflammation and development of inflammatory disorders, such as atherosclerosis and autoimmune diseases.

Emerging evidence suggests that macrophage function is regulated by alterations in their cellular metabolism in response to environmental cues within the inflammatory milieu. For instance, specific metabolic components may promote or suppress inflammatory responses in macrophages. Importantly, efferocytosis also promotes immunometabolic reprograming in macrophages (Figure 2). For example, digestion of the engulfed apoptotic cargo through phagolysosomal activity results in a load of lipid components derived from the apoptotic cell membranes that is linked to enhanced fatty acid oxidation and regulates macrophage function. The mechanisms underlying apoptotic cell removal by macrophages as well as the immunometabolic alterations in efferocytic macrophages during inflammation resolution is the focus of the present review.

Molecular Cross-Talk Between Apoptotic Cells and Macrophages During Efferocytosis

The engulfment of dying cells by efferocytic macrophages requires the recognition of the former by the latter and the formation of the engulfment synapse, which is regulated by a network of “find-me,” “eat-me” and bridging molecules, “don’t eat-me” signals and specialized phagocytic receptors (Figure 1). Neutrophils undergoing apoptosis during an inflammatory response, secrete molecules serving as “find-me” signals that can attract phagocytes to eliminate apoptotic cell corpses. These include the nucleotides adenosine triphosphate (ATP) and uridine triphosphate (UTP), which are recognized by the macrophage purinergic receptor P2Y2, or the lipids lysophosphatidylcholine (LPC) and sphingosine-1-phosphate, which bind to macrophage G-protein-coupled receptors G2A and S1P1-5, respectively. Furthermore, recognition of dying cells by macrophages may be facilitated by the interaction of intercellular adhesion molecule 3 (ICAM3 or CD50) on the former with CD14 on macrophages as well as by the thrombospondin (TSP1)–CD36 interaction. Moreover, the specific recognition of apoptotic cells is ensured by the presence of “eat-me” signals. PS is the most well characterized “eat-me” signal (Figure 1). During apoptosis, this phospholipid is found on the outer part of the membrane and binds directly or indirectly, via bridging molecules (opsonins), to phagocytic receptors. Calreticulin (Crt) is a membrane-associated protein that functions as an “eat-me” signal’ on the surface of dying cells and is recognized by the LDL-receptor-related protein 1 (LRP1 or CD91) on phagocytes. The long pentraxin PTX3 may also act as an “eat-me” signal to facilitate the capture of dying neutrophils by macrophages.

As alluded to above, bridging molecules are often key to efficient interactions between apoptotic neutrophils and macrophages. Milk fat globule-EGF factor 8 protein (MFG-E8 or lactadherin) promotes efferocytosis by binding to PS on apoptotic cells and to macrophage phagocytic integrin receptors αvβ3 and αvβ5. MFG-E8 shares homology with developmental endothelial locus-1 (DEL-1). Besides the established anti-inflammatory role of DEL-1 as inhibitor of β2 integrin-dependent leukocyte recruitment and IL-17-mediated inflammation and its role as a regulator of bone marrow myelopoiesis, secreted DEL-1 promotes engulfment of apoptotic cells and inflammation resolution. In particular, DEL-1 functions as a molecular bridge that binds concomitantly to PS on the apoptotic neutrophil surface via its C-terminal discoidin I-like domains and to αvβ3 integrin [also known as vitronectin receptor] on macrophages via its N-terminal RGD motif within the second EGF-like domain. Importantly, the compartmentalized localization of DEL-1 differentially regulates the inflammatory response. Specifically, the endothelial cell-derived molecule promotes anti-inflammatory activity by blocking β2 integrin-dependent leukocyte recruitment, whereas DEL-1 derived from macrophages promotes efferocytosis-dependent resolution of inflammation (Figure 1). Other molecules that act as a molecular bridge to facilitate interactions between apoptotic cargo and phagocytes include annexin A1 or lipocortin-1, β2-glycoprotein-I (β2-GPI), and galectin-3 (Gal-3). Moreover, the bridging molecules Growth arrest-specific factor 6 (Gas6) and protein S have been implicated in PS-mediated apoptotic cell clearance via interacting with the receptor tyrosine kinases Tyro-3, Axl and Mer (TAM) (Figure 1).

Phagocytic receptors on macrophages involved in the regulation of efferocytosis include also the PS receptors of the T-cell membrane protein (Tim) family, such as TIM-1 and TIM-4. The brain angiogenesis inhibitor 1 (BAI1) and stabilin-2 also serve as PS receptors (Figure 1). Additionally, CD14, the scavenger receptor CD36, and the integrin CD11b/CD18 (αMβ2) (besides the integrins αvβ5 and αvβ3 that were mentioned above) are implicated as efferocytosis receptors.

The presence of “don’t eat-me” signals further adds to the complexity of the regulation of apoptotic cell clearance. Specifically, surface expression of CD47 (also named integrin-associated protein) prevents phagocytosis by macrophages. Binding of CD47 to the macrophage signal regulatory protein alpha (SIRPα) modulates rearrangement of actin cytoskeleton, thereby downregulating phagocytosis. However, apoptotic cells have decreased levels of CD47 that allows their clearance by macrophages. Platelet and endothelial cell adhesion molecule 1 (PECAM-1, CD31) also exerts a “don’t eat-me” function. In this regard, homotypic CD31 interaction between non-apoptotic neutrophils and macrophages may prevent phagocytic clearance. Furthermore, CD24 and the complement receptor CD46 have been described as repulsive signals that interfere with efferocytosis. Decreased presence or alterations in the distribution of “don’t eat-me” signals have been associated with enhanced efferocytic activity.

Efficient efferocytosis is critical for shaping the pro-resolving phenotype in macrophages that includes production of immunomodulators, which in turn further enhance resolution of inflammation. For instance, production of TGFβ by efferocytic macrophages is a major orchestrator of inflammation resolution. Indeed, upregulation of TGFβ owing to efferocytosis promotes downregulation of the pro-inflammatory mediators TNF, IL-1β and IL-8. Consistently, antibody-mediated inhibition of TGFβ restored expression of inflammatory mediators. Along the same line, administration of apoptotic cells in vivo models of inflammation triggers resolution of inflammation in a manner dependent on TGFβ upregulation. Additionally, interleukin 13 derived from regulatory T cells acts on macrophages and promotes production of IL-10, which in turn enhances efferocytosis via activation of Rac1 GTPase and thereby inflammation resolution in atherosclerosis. Besides the upregulation of immune-modulating factors, such as TGFβ or IL-10, the direct inhibition of pro-inflammatory cytokines further contributes to inflammation resolution. As an exemplar, formation of NETs that aggregate at the inflamed site leads to protease–dependent degradation of inflammatory cytokines and chemokines, thereby promoting resolution of acute neutrophilic inflammation.

The phenotype of efferocytic macrophages is additionally controlled by the enzyme 12/15 lipoxygenase (12/15-LO) that oxidizes polyunsaturated fatty acids and generates bioactive lipid metabolites leading to the biosynthesis of pro-resolving lipid mediators. Specifically, apoptotic cell engulfment can be performed by resident or monocyte-derived resolution phase macrophages expressing 12/15-LO. Apoptotic cell engulfment further promotes the expression of this enzyme. Moreover, 12/15-LO has been implicated to function in preventing induction of autoimmunity.

Plasminogen and its cleavage product plasmin not only regulate the initiation but also the resolution phase of inflammation. Treatment of mice with plasminogen/plasmin resulted in recruitment of pro-resolving macrophages and in upregulation of TGFβ. Administration of plasminogen/plasmin at the peak of inflammation was associated with increased neutrophil apoptosis and efferocytosis; the pro-resolving effect of plasminogen was mediated by annexin A1. In accordance, impaired efferocytosis accompanied by decreased levels of annexin A1 was observed in mice deficient in plasminogen or its receptor. Besides being involved in pro-resolving actions of plasminogen, annexin A1 plays a broader role in inflammation resolution. Annexin A1 levels are increased in the resolution phase of monosodium urate crystal–induced arthritis, a model of gout. Pharmacologic or genetic inactivation of annexin A1 resulted in insufficient resolution of gout-related inflammation in mice. In addition, treatment of mice with annexin A1 resulted in upregulation of IL-10 and downregulation of proinflammatory mediators, while, consistently, inhibition of annexin A1 abrogated inflammation resolution induced by glucocorticoids.

Moreover, IFN-β from macrophages was recently identified as a factor promoting resolution of inflammation. IFN-β levels were higher in the resolution phase of pneumonia and peritoneal inflammation. Activation of IFN-β signaling via STAT3 enhances apoptosis of neutrophils and their subsequent efferocytic clearance, resulting in a pro-resolving reprograming of macrophages.

Metabolic Modulation of Macrophage Function in the Context of Efferocytosis

The impact of cellular metabolism on macrophage function and plasticity has gained much attention recently. Metabolic pathways, such as glycolysis, tricarboxylic acid (TCA) cycle, pentose phosphate pathway and fatty acid oxidation, regulate macrophage phenotype in the context of inflammatory responses. For instance, increased glycolytic flux has been linked to pro-inflammatory M1-like activation of macrophages, whereas oxidative phosphorylation is associated with anti-inflammatory macrophage polarization.

Moreover, macrophage tissue specificity may be associated with differential metabolic activity. For example, resident peritoneal macrophage survival depends on the transcription factor GATA6 that is regulated by the vitamin A metabolite retinoic acid, while the nuclear receptor liver × receptor (LXR) alpha that is activated by lipids regulates differentiation of marginal zone splenic macrophages. It is now established that tissue-specific resident macrophages have distinct transcriptomic profiles and phenotypes depending on the particular microenvironment. Importantly, in this regard, the manner by which efferocytosis is regulated in resident macrophages may be dictated by the tissue microenvironment. Indeed, parabiosis-based experiments have revealed substantial heterogeneity in the utilization of bridging molecules, efferocytic receptors and transcription factors by macrophages from different tissues. For instance, the mannose receptor CD206 is upregulated in phagocytic macrophages in bone marrow and intestine but not in the spleen. Moreover, the profile of upregulated anti-inflammatory mediators by efferocytic macrophages is tissue-specific.

Regulation of macrophage metabolic activity in the context of efferocytosis (Figure 2) is of major importance for the outcome of inflammation resolution and tissue repair. Following engulfment, macrophages degrade the apoptotic material through phagolysosomal activity, resulting in substantial metabolic load and influence on macrophage metabolism.

Aerobic glycolysis was recently implicated in regulation of efferocytosis and shaping an anti-inflammatory environment by efferocytic macrophages. Specifically, transcriptomic analysis of macrophages engaging in active phagocytosis of apoptotic cells revealed an upregulation of several members of the solute carrier (SLC) membrane transport protein family, including the glucose transporter protein type 1 (GLUT1; encoded by the gene Slc2a1) and monocarboxylate transporter 1 (encoded by Slc16a1) promoting lactate release. Enhanced glycolysis in efferocytic macrophages promoted actin polymerization and continued uptake of apoptotic cells. On the other hand, lactate from efferocytic macrophages contributed to establishment of an anti-inflammatory phenotype of the surrounding tissue (Figure 2). Consistently, knockdown of Slc16a1 in the setting of efferocytosis resulted in reduced mRNA expression of factors linked to the resolving macrophage phenotype and resolution of inflammation, such as Tgfb1 and Il10. Furthermore, specific deletion of GLUT1 in myeloid cells was associated with defective phagocytic ability of macrophages and with development of unstable lesions in a model of atherosclerosis. Moreover, deficiency of the glycolytic enzyme 6-phosphofructose-2-kinase and fructose-2,6-bisphosphatase (PFKFB3) in macrophages led to reduced efferocytosis capacity, thus further supporting a role for glycolysis in apoptotic cell clearance.

Metabolites derived from engulfed apoptotic cells serve to fine-tune the process of efferocytosis and resolution of inflammation. Apoptotic cells are a source of the amino acids arginine and ornithine that are metabolized in macrophages to putrescine. This metabolic process enables continual rounds of efferocytosis (Figure 2). Putrescine enhances, via the RNA-binding protein HuR, the mRNA stabilization of the GTP-exchange factor Dbl. Dbl in turn activates the GTPase Rac1, resulting in changes in the actin cytoskeleton that facilitate further apoptotic cell engulfment. Exogenous administration of putrescine increases inflammation resolution in the context of atherosclerosis. Consistently, deficiency in myeloid cells of either the enzyme arginase 1 (Arg1), which converts arginine to ornithine, or the enzyme ornithine decarboxylase (ODC), which mediates the decarboxylation of ornithine to putrescine (Figure 2), is associated with efferocytic dysfunction and defective atherosclerosis resolution.

Several lines of evidence support also an important role of mitochondrial metabolism on the modulation of efferocytosis and efferocytosis-dependent resolution of inflammation. Metabolomic analysis of macrophages that have engulfed apoptotic material revealed metabolic reprograming of efferocytic macrophages toward fatty acid oxidation. Specifically, upregulation of pro-resolving IL-10 in efferocytic macrophages was mediated by mitochondrial beta-oxidation and induction of sirtuin1 signaling (Figure 2). The interplay between mitochondrial activity and effective efferocytosis was also illustrated by analyzing the function of mitochondrial uncoupling protein 2 (Ucp2). Besides its function in uncoupling oxidative phosphorylation from synthesis of ATP, Ucp2 can promote efferocytosis by reducing the mitochondrial membrane potential of macrophages. In the same vein, deficiency of Ucp2 resulted in defective apoptotic cell removal and was associated with development of atherosclerosis, whereas overexpression of Ucp2 enhanced efferocytosis. Additionally, dynamic alterations in mitochondrial physiology may dictate the outcome of efferocytosis. In particular, a major component of mitochondrial homeostasis, mitochondrial fission, mediated by the function of the GTPase dynamin-related protein 1 (Drp1), positively regulates continuous apoptotic cell removal by macrophages. Accordingly, the absence of Drp1 was associated with higher atherosclerosis development in low-density lipoprotein receptor 1 (Ldlr1) deficient mice.

Lipids deriving from the apoptotic cargo are abundant post-engulfment digestion products; lipid metabolism induces activation of the nuclear receptors peroxisome proliferator-activated receptor (PPAR) gamma and delta, LXR alpha and beta and retinoid × receptor (RXR) alpha and beta in macrophages (Figure 2). Activation of these transcription factors promotes upregulation of phagocytic receptors and bridging molecules and the resolving macrophage phenotype. For instance, TGFβ and IL-10, which both promote inflammation resolution, are upregulated in efferocytic macrophages in an LXR- and PPAR delta–dependent manner. Importantly, deficiency of these nuclear receptors has been linked to defective efferocytosis and development of chronic inflammation or autoimmune manifestations. Moreover, LXR activation is involved in DEL-1–dependent efferocytosis and macrophage reprograming to a proresolving phenotype. LXR signaling also regulates expression of transglutaminase 2 (Tgm2), which acts as a co-receptor to αvβ3-integrin and promotes formation of engulfing portals.

Cholesterol metabolism has been also implicated in the modulation of efferocytosis. Treatment of macrophages with the cholesterol-lowering drug lovastatin, which inhibits the rate-limiting enzyme of cholesterol synthesis 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase, leads to increased apoptotic cell clearance. Administration of another HMG-CoA reductase inhibitor, simvastatin, enhances the efferocytosis-dependent amelioration of inflammation in the context of lung fibrosis. Along the same line, the ATP-binding cassette transporter (ABCA1), a protein that modulates cholesterol efflux, is upregulated during efferocytosis in a manner dependent on LXR signaling. Furthermore, decreased hydrolysis of cholesterol esters and impaired oxysterol production, due to blockade of the enzyme lysosomal acid lipase, negatively affect LXR pathway activation and apoptotic cell removal, resulting in chronic inflammation. These studies point to the intimate crosstalk between cholesterol metabolism and nuclear receptor signaling involved in efferocytosis.

Concluding Remarks

Macrophage efferocytosis is a major player in resolution of inflammation. Efferocytosis not only paves the way toward the timely termination of the inflammatory response, but also promotes restoration of tissue homeostasis. In this context, alterations in macrophage cellular metabolism are important regulators of efferocytosis. At the same time, metabolic reprograming in efferocytic macrophages induced by digested apoptotic material substantially regulates the function and plasticity of efferocytic macrophages. Given the relevance of efferocytosis as a mechanism against chronic inflammatory disease, a better mechanistic understanding of the pathways that orchestrate the mutual interaction between clearance of dying cells and metabolic alterations in macrophages is required. This knowledge will provide a scaffold for designing therapeutic approaches to improve macrophage function in inflammation resolution and harness macrophage efferocytosis for the treatment of pathologies associated with chronic inflammation or autoimmunity.

Author Contributions

IK, GH, and TC wrote the manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 115

  1. 1.
    Phagocytosis: A Fundamental Process in Immunity · 2017
    No notice
  2. 2.

    Stuart LM Ezekowitz RA. Phagocytosis: elegant complexity. Immunity. (2005 ) 22:539–50.

    Not in our library10.1016/j.immuni.2005.05.002

  3. 3.
    Resolution of inflammation: an integrated view · 2013
    No notice
  4. 4.

    Hajishengallis G Chavakis T Hajishengallis E Lambris JD. Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis. J Leukoc Biol. (2015 ) 98:539–48.

    Not in our library10.1189/jlb.3vmr1014-468r

  5. 5.

    Soehnlein O Steffens S Hidalgo A Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol. (2017 ) 17:248–61.

    Not in our library10.1038/nri.2017.10

  6. 6.

    Ley K Hoffman HM Kubes P Cassatella MA Zychlinsky A Hedrick CC Neutrophils: new insights and open questions. Sci Immunol. (2018 ) 3:eaat4579.

    Not in our library10.1126/sciimmunol.aat4579

  7. 7.

    Doran AC Yurdagul A Jr. Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. (2019 ). [Epub ahead of print].

    Not in our library10.1038/s41577-019-0240-6

  8. 8.

    Kourtzelis I Mitroulis I von Renesse J Hajishengallis G Chavakis T. From leukocyte recruitment to resolution of inflammation: the cardinal role of integrins. J Leukoc Biol. (2017 ) 102:677–83.

    Not in our library10.1189/jlb.3mr0117-024r

  9. 9.

    Serhan CN Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. (2018 ) 128:2657–69.

    Not in our library10.1172/jci97943

  10. 10.

    Headland SE Norling LV. The resolution of inflammation: principles and challenges. Semin Immunol. (2015 ) 27:149–60.

    Not in our library10.1016/j.smim.2015.03.014

  11. 11.

    Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med. (2010 ) 207:1807–17.

    Not in our library10.1084/jem.20101157

  12. 12.

    Serhan CN Chiang N Dalli J Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol. (2014 ) 7:a016311.

    Not in our library10.1101/cshperspect.a016311

  13. 13.

    Fond AM Ravichandran KS. Clearance of dying cells by phagocytes: mechanisms and implications for disease pathogenesis. Adv Exp Med Biol. (2016 ) 930:25–49.

    Not in our library10.1007/978-3-319-39406-0_2

  14. 14.

    Thorp E Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol. (2009 ) 86:1089–95.

    Not in our library10.1189/jlb.0209115

  15. 15.

    Kawano M Nagata S. Efferocytosis and autoimmune disease. Int Immunol. (2018 ) 30:551–8.

    Not in our library10.1093/intimm/dxy055

  16. 16.

    O’Neill LA Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med. (2016 ) 213:15–23.

    Not in our library10.1084/jem.20151570

  17. 17.

    Stunault MI Bories G Guinamard RR Ivanov S. Metabolism plays a key role during macrophage activation. Mediators Inflamm. (2018 ) 2018:2426138.

    Not in our library10.1155/2018/2426138

  18. 18.

    Zhang S Weinberg S DeBerge M Gainullina A Schipma M Kinchen JM Efferocytosis fuels requirements of fatty acid oxidation and the electron transport chain to polarize macrophages for tissue repair. Cell Metab. (2019 ) 29:443–56.e5.

    Not in our library10.1016/j.cmet.2018.12.004

  19. 19.

    Park D Han CZ Elliott MR Kinchen JM Trampont PC Das S Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein. Nature. (2011 ) 477:220–4.

    Not in our library10.1038/nature10340

  20. 20.

    Park SY Kim IS. Engulfment signals and the phagocytic machinery for apoptotic cell clearance. Exp Mol Med. (2017 ) 49:e331.

    Not in our library10.1038/emm.2017.52

  21. 21.

    Medina CB Ravichandran KS. Do not let death do us part: ‘find-me’ signals in communication between dying cells and the phagocytes. Cell Death Differ. (2016 ) 23:979–89.

    Not in our library10.1038/cdd.2016.13

  22. 22.

    Elliott MR Chekeni FB Trampont PC Lazarowski ER Kadl A Walk SF Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. (2009 ) 461:282–6.

    Not in our library10.1038/nature08296

  23. 23.

    Lauber K Bohn E Krober SM Xiao YJ Blumenthal SG Lindemann RK Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell. (2003 ) 113:717–30.

    Not in our library10.1016/s0092-8674(03)00422-7

  24. 24.

    Gude DR Alvarez SE Paugh SW Mitra P Yu J Griffiths R Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. FASEB J. (2008 ) 22:2629–38.

    Not in our library10.1096/fj.08-107169

  25. 25.

    Moffatt OD Devitt A Bell ED Simmons DL Gregory CD. Macrophage recognition of ICAM-3 on apoptotic leukocytes. J Immunol. (1999 ) 162:6800–10.

    Not in our library

  26. 26.

    Savill J Hogg N Ren Y Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest. (1992 ) 90:1513–22.

    Not in our library10.1172/jci116019

  27. 27.

    Elliott MR Ravichandran KS. The dynamics of apoptotic cell clearance. Dev Cell. (2016 ) 38:147–60.

    Not in our library10.1016/j.devcel.2016.06.029

  28. 28.

    Poon IK Lucas CD Rossi AG Ravichandran KS. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol. (2014 ) 14:166–80.

    Not in our library10.1038/nri3607

  29. 29.

    Gardai SJ McPhillips KA Frasch SC Janssen WJ Starefeldt A Murphy-Ullrich JE Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. (2005 ) 123:321–34.

    Not in our library10.1016/j.cell.2005.08.032

  30. 30.

    Jaillon S Jeannin P Hamon Y Fremaux I Doni A Bottazzi B Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ. (2009 ) 16:465–74.

    Not in our library10.1038/cdd.2008.173

  31. 31.

    Hanayama R Tanaka M Miyasaka K Aozasa K Koike M Uchiyama Y Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science. (2004 ) 304:1147–50.

    Not in our library10.1126/science.1094359

  32. 32.

    Hanayama R Tanaka M Miwa K Shinohara A Iwamatsu A Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature. (2002 ) 417:182–7.

    Not in our library10.1038/417182a

  33. 33.

    Hajishengallis G Chavakis T. DEL-1-regulated immune plasticity and inflammatory disorders. Trends Mol Med. (2019 ) 25:444–59.

    Not in our library10.1016/j.molmed.2019.02.010

  34. 34.

    Choi EY Chavakis E Czabanka MA Langer HF Fraemohs L Economopoulou M Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science. (2008 ) 322:1101–4.

    Not in our library10.1126/science.1165218

  35. 35.

    Kourtzelis I Kotlabova K Lim JH Mitroulis I Ferreira A Chen LS Developmental endothelial locus-1 modulates platelet-monocyte interactions and instant blood-mediated inflammatory reaction in islet transplantation. Thromb Haemost. (2016 ) 115:781–8.

    Not in our library10.1160/th15-05-0429

  36. 36.

    Mitroulis I Alexaki VI Kourtzelis I Ziogas A Hajishengallis G Chavakis T. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. (2015 ) 147:123–35.

    Not in our library10.1016/j.pharmthera.2014.11.008

  37. 37.

    Hajishengallis G Chavakis T. Endogenous modulators of inflammatory cell recruitment. Trends Immunol. (2013 ) 34:1–6.

    Not in our library10.1016/j.it.2012.08.003

  38. 38.

    Shin J Maekawa T Abe T Hajishengallis E Hosur K Pyaram K DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates. Sci Transl Med. (2015 ) 7:307ra155.

    Not in our library10.1126/scitranslmed.aac5380

  39. 39.

    Chavakis T Mitroulis I Hajishengallis G. Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. Nat Immunol. (2019 ) 20:802–11.

    Not in our library10.1038/s41590-019-0402-5

  40. 40.

    Mitroulis I Chen LS Singh RP Kourtzelis I Economopoulou M Kajikawa T Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche. J Clin Invest. (2017 ) 127:3624–39.

    Not in our library10.1172/jci92571

  41. 41.

    Kourtzelis I Li X Mitroulis I Grosser D Kajikawa T Wang B DEL-1 promotes macrophage efferocytosis and clearance of inflammation. Nat Immunol. (2019 ) 20:40–9.

    Not in our library10.1038/s41590-018-0249-1

  42. 42.

    Savill J Dransfield I Hogg N Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature. (1990 ) 343:170–3.

    Not in our library10.1038/343170a0

  43. 43.

    Hanayama R Tanaka M Miwa K Nagata S. Expression of developmental endothelial locus-1 in a subset of macrophages for engulfment of apoptotic cells. J Immunol. (2004 ) 172:3876–82.

    Not in our library10.4049/jimmunol.172.6.3876

  44. 44.

    Arur S Uche UE Rezaul K Fong M Scranton V Cowan AE Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev Cell. (2003 ) 4:587–98.

    Not in our library10.1016/s1534-5807(03)00090-x

  45. 45.

    Balasubramanian K Schroit AJ. Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem. (1998 ) 273:29272–7.

    Not in our library10.1074/jbc.273.44.29272

  46. 46.

    Caberoy NB Alvarado G Bigcas JL Li W. Galectin-3 is a new MerTK-specific eat-me signal. J Cell Physiol. (2012 ) 227:401–7.

    Not in our library10.1002/jcp.22955

  47. 47.

    Anderson HA Maylock CA Williams JA Paweletz CP Shu H Shacter E. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol. (2003 ) 4:87–91.

    Not in our library10.1038/ni871

  48. 48.

    Lemke G Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann N Y Acad Sci. (2010 ) 1209:23–9.

    Not in our library10.1111/j.1749-6632.2010.05744.x

  49. 49.

    Scott RS McMahon EJ Pop SM Reap EA Caricchio R Cohen PL Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. (2001 ) 411:207–11.

    Not in our library10.1038/35075603

  50. 50.

    Rothlin CV Ghosh S Zuniga EI Oldstone MB Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. (2007 ) 131:1124–36.

    Not in our library10.1016/j.cell.2007.10.034

  51. 51.

    Lemke G Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. (2008 ) 8:327–36.

    Not in our library10.1038/nri2303

  52. 52.

    Lumbroso D Soboh S Maimon A Schif-Zuck S Ariel A Burstyn-Cohen T. Macrophage-derived protein S facilitates apoptotic polymorphonuclear cell clearance by resolution phase macrophages and supports their reprogramming. Front Immunol. (2018 ) 9:358.

    Not in our library10.3389/fimmu.2018.00358

  53. 53.

    Miyanishi M Tada K Koike M Uchiyama Y Kitamura T Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature. (2007 ) 450:435–9.

    Not in our library10.1038/nature06307

  54. 54.

    Kobayashi N Karisola P Pena-Cruz V Dorfman DM Jinushi M Umetsu SE TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. (2007 ) 27:927–40.

    Not in our library10.1016/j.immuni.2007.11.011

  55. 55.

    Park D Tosello-Trampont AC Elliott MR Lu M Haney LB Ma Z BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature. (2007 ) 450:430–4.

    Not in our library10.1038/nature06329

  56. 56.

    Park SY Jung MY Kim HJ Lee SJ Kim SY Lee BH Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. (2008 ) 15:192–201.

    Not in our library10.1038/sj.cdd.4402242

  57. 57.

    Mevorach D Mascarenhas JO Gershov D Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med. (1998 ) 188:2313–20.

    Not in our library10.1084/jem.188.12.2313

  58. 58.

    Devitt A Moffatt OD Raykundalia C Capra JD Simmons DL Gregory CD. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature. (1998 ) 392:505–19.

    Not in our library10.1038/33169

  59. 59.

    Oldenborg PA Zheleznyak A Fang YF Lagenaur CF Gresham HD Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. (2000 ) 288:2051–4.

    Not in our library10.1126/science.288.5473.2051

  60. 60.

    Oldenborg PA Gresham HD Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. (2001 ) 193:855–62.

    Not in our library10.1084/jem.193.7.855

  61. 61.

    Kojima Y Volkmer JP McKenna K Civelek M Lusis AJ Miller CL CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. (2016 ) 536:86–90.

    Not in our library10.1038/nature18935

  62. 62.

    Brown S Heinisch I Ross E Shaw K Buckley CD Savill J. Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature. (2002 ) 418:200–3.

    Not in our library10.1038/nature00811

  63. 63.

    Barkal AA Brewer RE Markovic M Kowarsky M Barkal SA Zaro BW CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. (2019 ) 572:392–6.

    Not in our library10.1038/s41586-019-1456-0

  64. 64.

    Elward K Griffiths M Mizuno M Harris CL Neal JW Morgan BP CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem. (2005 ) 280:36342–54.

    Not in our library10.1074/jbc.m506579200

  65. 65.

    Barth ND Marwick JA Vendrell M Rossi AG Dransfield I. The “Phagocytic Synapse” and clearance of apoptotic cells. Front Immunol. (2017 ) 8:1708.

    Not in our library10.3389/fimmu.2017.01708

  66. 66.

    Kinchen JM Ravichandran KS. Phagocytic signaling: you can touch, but you can’t eat. Curr Biol. (2008 ) 18:R521–4.

    Not in our library10.1016/j.cub.2008.04.058

  67. 67.

    Ariel A Serhan CN. New lives given by cell death: macrophage differentiation following their encounter with apoptotic leukocytes during the resolution of inflammation. Front Immunol. (2012 ) 3:4.

    Not in our library10.3389/fimmu.2012.00004

  68. 68.

    Bratton DL Henson PM. Neutrophil clearance: when the party is over, clean-up begins. Trends Immunol. (2011 ) 32:350–7.

    Not in our library10.1016/j.it.2011.04.009

  69. 69.

    Henson PM. Cell removal: efferocytosis. Annu Rev Cell Dev Biol. (2017 ) 33:127–44.

    Not in our library10.1146/annurev-cellbio-111315-125315

  70. 70.

    Henson PM Bratton DL. Antiinflammatory effects of apoptotic cells. J Clin Invest. (2013 ) 123:2773–4.

    Not in our library10.1172/jci69344

  71. 71.

    Sugimoto MA Vago JP Perretti M Teixeira MM. Mediators of the resolution of the inflammatory response. Trends Immunol. (2019 ) 40:212–27.

    Not in our library10.1016/j.it.2019.01.007

  72. 72.

    Fadok VA Bratton DL Konowal A Freed PW Westcott JY Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. (1998 ) 101:890–8.

    Not in our library10.1172/jci1112

  73. 73.

    Huynh ML Fadok VA Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. (2002 ) 109:41–50.

    Not in our library10.1172/jci11638

  74. 74.

    Proto JD Doran AC Gusarova G Yurdagul A Jr. Sozen E Subramanian M Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity. (2018 ) 49:666–77.e6.

    Not in our library10.1016/j.immuni.2018.07.015

  75. 75.

    Schauer C Janko C Munoz LE Zhao Y Kienhofer D Frey B Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. (2014 ) 20:511–7.

    Not in our library10.1038/nm.3547

  76. 76.

    Levy BD Clish CB Schmidt B Gronert K Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. (2001 ) 2:612–9.

    Not in our library10.1038/89759

  77. 77.

    Uderhardt S Herrmann M Oskolkova OV Aschermann S Bicker W Ipseiz N 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity. (2012 ) 36:834–46.

    Not in our library10.1016/j.immuni.2012.03.010

  78. 78.

    Stables MJ Shah S Camon EB Lovering RC Newson J Bystrom J Transcriptomic analyses of murine resolution-phase macrophages. Blood. (2011 ) 118:e192–208.

    Not in our library10.1182/blood-2011-04-345330

  79. 79.
    IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation · 2019
    No notice
  80. 80.

    Schif-Zuck S Gross N Assi S Rostoker R Serhan CN Ariel A. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol. (2011 ) 41:366–79.

    Not in our library10.1002/eji.201040801

  81. 81.

    Freire-de-Lima CG Xiao YQ Gardai SJ Bratton DL Schiemann WP Henson PM. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem. (2006 ) 281:38376–84.

    Not in our library10.1074/jbc.m605146200

  82. 82.

    Sugimoto MA Ribeiro ALC Costa BRC Vago JP Lima KM Carneiro FS Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1. Blood. (2017 ) 129:2896–907.

    Not in our library10.1182/blood-2016-09-742825

  83. 83.

    Vago JP Sugimoto MA Lima KM Negreiros-Lima GL Baik N Teixeira MM Plasminogen and the plasminogen receptor, Plg-RKT, regulate macrophage phenotypic, and functional changes. Front Immunol. (2019 ) 10:1458.

    Not in our library10.3389/fimmu.2019.01458

  84. 84.

    Sousa LP Alessandri AL Pinho V Teixeira MM. Pharmacological strategies to resolve acute inflammation. Curr Opin Pharmacol. (2013 ) 13:625–31.

    Not in our library10.1016/j.coph.2013.03.007

  85. 85.
    Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance · 2016
    No notice
  86. 86.

    Galvao I Vago JP Barroso LC Tavares LP Queiroz-Junior CM Costa VV Annexin A1 promotes timely resolution of inflammation in murine gout. Eur J Immunol. (2017 ) 47:585–96.

    Not in our library10.1002/eji.201646551

  87. 87.

    Souza DG Fagundes CT Amaral FA Cisalpino D Sousa LP Vieira AT The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol. (2007 ) 179:8533–43.

    Not in our library10.4049/jimmunol.179.12.8533

  88. 88.

    Vago JP Nogueira CR Tavares LP Soriani FM Lopes F Russo RC Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis. J Leukoc Biol. (2012 ) 92:249–58.

    Not in our library10.1189/jlb.0112008

  89. 89.

    O’Neill LA Kishton RJ Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. (2016 ) 16:553–65.

    Not in our library10.1038/nri.2016.70

  90. 90.

    Pearce EL Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. (2013 ) 38:633–43.

    Not in our library10.1016/j.immuni.2013.04.005

  91. 91.

    Van den Bossche J O’Neill LA Menon D. Macrophage immunometabolism: where are we (going)? Trends Immunol. (2017 ) 38:395–406.

    Not in our library10.1016/j.it.2017.03.001

  92. 92.
    Metabolic Modulation in Macrophage Effector Function · 2018
    No notice
  93. 93.

    Rosas M Davies LC Giles PJ Liao CT Kharfan B Stone TC The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science. (2014 ) 344:645–8.

    Not in our library10.1126/science.1251414

  94. 94.

    Okabe Y Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell. (2014 ) 157:832–44.

    Not in our library10.1016/j.cell.2014.04.016

  95. 95.

    A-Gonzalez N Guillen JA Gallardo G Diaz M de la Rosa JV Hernandez IH The nuclear receptor LXRalpha controls the functional specialization of splenic macrophages. Nat Immunol. (2013 ) 14:831–9.

    Not in our library10.1038/ni.2622

  96. 96.
    Tissue‐resident macrophages: then and now · 2015
    No notice
  97. 97.

    Gautier EL Shay T Miller J Greter M Jakubzick C Ivanov S Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. (2012 ) 13:1118–28.

    Not in our library10.1038/ni.2419

  98. 98.

    A-Gonzalez N Quintana JA Garcia-Silva S Mazariegos M Gonzalez de la Aleja A Nicolas-Avila JA Phagocytosis imprints heterogeneity in tissue-resident macrophages. J Exp Med. (2017 ) 214:1281–96.

    Not in our library10.1084/jem.20161375

  99. 99.

    Han CZ Ravichandran KS. Metabolic connections during apoptotic cell engulfment. Cell. (2011 ) 147:1442–5.

    Not in our library10.1016/j.cell.2011.12.006

  100. 100.

    Hochreiter-Hufford A Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol. (2013 ) 5:a008748.

    Not in our library10.1101/cshperspect.a008748

  101. 101.

    Green DR Oguin TH Martinez J. The clearance of dying cells: table for two. Cell Death Differ. (2016 ) 23:915–26.

    Not in our library10.1038/cdd.2015.172

  102. 102.

    Morioka S Perry JSA Raymond MH Medina CB Zhu Y Zhao L Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. (2018 ) 563:714–8.

    Not in our library10.1038/s41586-018-0735-5

  103. 103.

    Freemerman AJ Zhao L Pingili AK Teng B Cozzo AJ Fuller AM Myeloid Slc2a1-deficient murine model revealed macrophage activation and metabolic phenotype are fueled by GLUT1. J Immunol. (2019 ) 202:1265–86.

    Not in our library10.4049/jimmunol.1800002

  104. 104.

    Jiang H Shi H Sun M Wang Y Meng Q Guo P PFKFB3-driven macrophage glycolytic metabolism is a crucial component of innate antiviral defense. J Immunol. (2016 ) 197:2880–90.

    Not in our library10.4049/jimmunol.1600474

  105. 105.

    Yurdagul A Jr. Subramanian M Wang X Crown SB Ilkayeva OR Darville L Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. (2020 ) 31:518–33.e10.

    Not in our library10.1016/j.cmet.2020.01.001

  106. 106.

    Wang Y Subramanian M Yurdagul A Jr. Barbosa-Lorenzi VC Cai B de Juan-Sanz J Mitochondrial fission promotes the continued clearance of apoptotic cells by macrophages. Cell. (2017 ) 171:331–45.e22.

    Not in our library10.1016/j.cell.2017.08.041

  107. 107.

    A-Gonzalez N Hidalgo A. Nuclear receptors and clearance of apoptotic cells: stimulating the macrophage’s appetite. Front Immunol. (2014 ) 5:211.

    Not in our library10.3389/fimmu.2014.00211

  108. 108.

    A-Gonzalez N Bensinger SJ Hong C Beceiro S Bradley MN Zelcer N Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. (2009 ) 31:245–58.

    Not in our library10.1016/j.immuni.2009.06.018

  109. 109.

    Mukundan L Odegaard JI Morel CR Heredia JE Mwangi JW Ricardo-Gonzalez RR PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med. (2009 ) 15:1266–72.

    Not in our library10.1038/nm.2048

  110. 110.

    Rebe C Raveneau M Chevriaux A Lakomy D Sberna AL Costa A Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ Res. (2009 ) 105:393–401.

    Not in our library10.1161/circresaha.109.201855

  111. 111.

    Toth B Garabuczi E Sarang Z Vereb G Vamosi G Aeschlimann D Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. J Immunol. (2009 ) 182:2084–92.

    Not in our library10.4049/jimmunol.0803444

  112. 112.

    Morimoto K Janssen WJ Fessler MB McPhillips KA Borges VM Bowler RP Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. (2006 ) 176:7657–65.

    Not in our library10.4049/jimmunol.176.12.7657

  113. 113.

    Lee YJ Kim MJ Yoon YS Choi YH Kim HS Kang JL. Simvastatin treatment boosts benefits of apoptotic cell infusion in murine lung fibrosis. Cell Death Dis. (2017 ) 8:e2860.

    Not in our library10.1038/cddis.2017.260

  114. 114.
    Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα · 2000
    Not checked
  115. 115.

    Viaud M Ivanov S Vujic N Duta-Mare M Aira LE Barouillet T Lysosomal cholesterol hydrolysis couples efferocytosis to anti-inflammatory oxysterol production. Circ Res. (2018 ) 122:1369–84.

    Not in our library10.1161/circresaha.117.312333

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.